Literature DB >> 2004331

Prostatic duct adenocarcinoma. Findings at radical prostatectomy.

W N Christensen1, G Steinberg, P C Walsh, J I Epstein.   

Abstract

Previous studies of prostatic duct adenocarcinoma have reported a poor prognosis, but they included few patients treated by radical prostatectomy. The authors studied 15 cases treated with radical prostatectomy to define more completely their pathologic features and determine the clinical outcome in these surgically treated patients. The study included morphometry and DNA image analysis using the CAS-200 system. The most common presentation was urinary outlet obstruction (n = 9), and most patients were clinical Stage B with palpable prostatic lesions (n = 12). Compared with acinar cancers of similar clinical stage, duct cancers were large (tumor volume, 8.4 +/- 10.0 cc) and occupied a large portion of the gland (23 +/- 21%). Duct cancers were in an advanced final pathologic stage with 93% having capsular penetration, 47% positive margins, 40% seminal vesicle invasion, and 27% positive pelvic lymph nodes. The DNA analysis on cells disaggregated from paraffin revealed that 54% of cases were diploid, 15% tetraploid, 8% aneuploid, and 23% tetraploid/aneuploid. On clinical follow-up, eight patients had no evidence of tumor at intervals ranging from 1 to 28 months, and seven patients (47%) had persistent tumor at intervals of 3 to 18 months. This study demonstrates that duct cancers are in an advanced pathologic stage by the time of presentation and have a much higher short-term failure rate after radical prostatectomy compared with acinar cancers.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004331     DOI: 10.1002/1097-0142(19910415)67:8<2118::aid-cncr2820670818>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Prostatic ductal adenocarcinoma mimicking villous adenoma of the urethra.

Authors:  Katsuaki Sato; Hironori Tachibana; Toyonori Tsuzuki; Yoshimichi Ueda; Shogo Katsuda
Journal:  Virchows Arch       Date:  2006-09-19       Impact factor: 4.064

2.  PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Authors:  Carlos L Morais; Mehsati Herawi; Antoun Toubaji; Roula Albadine; Jessica Hicks; George J Netto; Angelo M De Marzo; Jonathan I Epstein; Tamara L Lotan
Journal:  Prostate       Date:  2015-07-14       Impact factor: 4.104

3.  Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment.

Authors:  Aalok Kumar; Som Dave Mukherjee
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

4.  Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.

Authors:  Catherine O'Brien; Lawrence D True; Celestia S Higano; Brooks L S Rademacher; Mark Garzotto; Tomasz M Beer
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

5.  Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma.

Authors:  Ali Amin; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2011-04       Impact factor: 6.394

6.  Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens.

Authors:  Amanda H Seipel; Fredrik Wiklund; N Peter Wiklund; Lars Egevad
Journal:  Virchows Arch       Date:  2013-02-27       Impact factor: 4.064

Review 7.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

8.  [Ductal Adenocarcinoma of the prostate with infiltration of the bladder. Can radical cystectomy and antiandrogen therapy cure the disease?].

Authors:  M Brock; W Martin; F Sommerer; J Noldus
Journal:  Urologe A       Date:  2009-07       Impact factor: 0.639

9.  Ductal adenocarcinoma of the prostate: a Hong Kong case series.

Authors:  Raymond Wai Man Kan; Chi Fai Kan; Joseph Hon Ming Wong; Kenneth Kam Fung Fu; Chi Fai Ng; Steve Wai Hee Chan
Journal:  Int Urol Nephrol       Date:  2014-07-31       Impact factor: 2.370

10.  TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.

Authors:  Tamara L Lotan; Antoun Toubaji; Roula Albadine; Mathieu Latour; Mehsati Herawi; Alan K Meeker; Angelo M DeMarzo; Elizabeth A Platz; Jonathan I Epstein; George J Netto
Journal:  Mod Pathol       Date:  2009-01-16       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.